AstraZeneca is looking for partnerships in Personalised healthcare and Biomarkers
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
Personalised Healthcare and Biomarkers (PHB)
Their Personalised Healthcare and Biomarkers (PHB) group aims to create superior outcomes for patients, prescribers and payers by finding the biomarkers and diagnostics that ensure they deliver effective medicines that target a selected patient population. They are looking for additional biomarker capabilities that can deliver clinically meaningful segmentation of therapeutic response, including methodology for patient selection, disease identification, and pharmacological assessment. They are also looking for external partners to identify, validate, and manufacture diagnostics to regulatory standards.